WP1130 Enhances TRAIL-Induced Apoptosis through USP9X-Dependent miR-708-Mediated Downregulation of c-FLIP
Seok Kim1, Seon Min Woo2, Kyoung-Jin Min3
1Department of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeoldaero, Dalseo-Gu, Daegu 42601, Korea. kimseok216@naver.com.
Abstract:
WP1130, a partially selective deubiquitinases (DUB) inhibitor, inhibits the deubiquitinating activities of USP5, USP9X, USP14, USP37, and UCHL1. In this study, we investigate whether WP1130 exerts sensitizing effect on TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human renal carcinoma cells. Combinations of WP1130 and TRAIL significantly induced apoptosis in renal carcinoma, lung carcinoma and hepatocellular carcinoma cells, but not in normal cells (human mesangial cells (MC) and normal mouse kidney cells (TCMK-1)). The downregulation of c-FLIP protein expression was involved in combined treatment-induced apoptosis. WP1130-induced c-FLIP downregulation was regulated by microRNA (miR)-708 upregulation via inhibition of USP9X. Interestingly, knockdown of USP9X markedly induced c-FLIP downregulation, upregulation of miR-708 expression and sensitivity to TRAIL. Furthermore, ectopic expression of USP9X prevented c-FLIP downregulation and apoptosis upon combined treatment. In sum, WP1130 sensitized TRAIL-induced apoptosis through miR-708-mediated downregulation of c-FLIP by inhibition of USP9X.
Insights
WP1130, a deubiquitinase inhibitor, enhances cancer cell apoptosis when combined with TRAIL therapy. This effect is mediated by USP9X inhibition, leading to reduced c-FLIP and increased sensitivity to TRAIL.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Deubiquitinase (DUB) inhibitors represent a promising therapeutic strategy in oncology.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis, but its clinical efficacy is often limited by resistance mechanisms.
- c-FLIP (FLICE-inhibitory protein) is a key regulator of apoptosis that can confer resistance to TRAIL-induced cell death.
Purpose of the Study:
- To investigate the sensitizing effect of WP1130, a DUB inhibitor, on TRAIL-induced apoptosis in human cancer cells.
- To elucidate the molecular mechanisms underlying the combined effect of WP1130 and TRAIL.
Main Methods:
- Treatment of human renal, lung, and hepatocellular carcinoma cell lines with WP1130 and TRAIL, alone and in combination.
- Assessment of apoptosis induction using cell viability assays.
- Analysis of c-FLIP protein expression levels.
- Investigation of the role of microRNA-708 (miR-708) and USP9X in the observed effects through gene knockdown and ectopic expression studies.
Main Results:
- Combination therapy with WP1130 and TRAIL significantly induced apoptosis in various cancer cell lines, including renal, lung, and hepatocellular carcinoma, while sparing normal cells.
- The combined treatment led to the downregulation of c-FLIP protein expression.
- WP1130-induced c-FLIP downregulation was mediated by the upregulation of miR-708, which was achieved through the inhibition of USP9X.
- Knockdown of USP9X mimicked the effects of WP1130, causing c-FLIP downregulation, miR-708 upregulation, and enhanced sensitivity to TRAIL. Ectopic expression of USP9X abrogated these effects.
Conclusions:
- WP1130 sensitizes cancer cells to TRAIL-induced apoptosis.
- The mechanism involves the inhibition of USP9X, leading to miR-708 upregulation and subsequent downregulation of c-FLIP.
- This study identifies a novel therapeutic strategy combining DUB inhibitors with TRAIL for cancer treatment.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Apoptosis
Self-Evaluation: Self-Enhancement and Self-Verification
Receptor-mediated Endocytosis
Frequency-dependent Selection
Drug Dependence


